EXAS - Exact Sciences Corporation
Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected.
Abbott Laboratories is upgraded to Buy ahead of Q2 2026 earnings, following a challenging period marked by share price underperformance. The recent acquisition of Exact Sciences adds a high-growth cancer diagnostics vertical, targeting $3bn incremental 2026 sales and potential long-term revenue expansion. 2026 guidance projects 6.5–7.5% organic sales growth and $5.38–$5.58 adjusted EPS, with Exact Sciences acquisition causing $0.20 EPS dilution.
Shares of Abbott Laboratories (NYSE:ABT) fell 3.2% on Thursday morning after the healthcare conglomerate marginally beat Wall Street estimates for quarterly profit and revenue, but flagged a hit to its 2026 earnings outlook from its recently completed cancer diagnostics acquisition. Investors weighed near-term earnings strength against dilution from the company's roughly $23 billion acquisition of Exact Sciences.
Capricorn Fund Managers Ltd acquired a new stake in shares of Exact Sciences Corporation (NASDAQ: EXAS) during the undefined quarter, according to its most recent disclosure with the SEC. The fund acquired 96,685 shares of the medical research company's stock, valued at approximately $9,819,000. Exact Sciences makes up about 2.4% of Capricorn Fund
Exchange Traded Concepts LLC cut its stake in Exact Sciences Corporation (NASDAQ: EXAS) by 39.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,044 shares of the medical research company's stock after selling 5,932 shares during the quarter. Exchange
FNY Investment Advisers LLC acquired a new position in shares of Exact Sciences Corporation (NASDAQ: EXAS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,500 shares of the medical research company's stock, valued at approximately $2,894,000. Exact Sciences accounts for about
Banque Pictet and Cie SA decreased its stake in Exact Sciences Corporation (NASDAQ: EXAS) by 77.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,415 shares of the medical research company's stock after selling 151,772 shares
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced four presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). The meeting will take place from April 17–22, 2026, in San Diego, CA. Exact Sciences will present new findings from the NSABP B-59/GBG-96-GeparDouze tri.
Bridgefront Capital LLC bought a new position in Exact Sciences Corporation (NASDAQ: EXAS) in the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 11,994 shares of the medical research company's stock, valued at approximately $656,000. Several other institutional investors have also recently made changes to their
ArrowMark Colorado Holdings LLC boosted its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 23.5% during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 597,931 shares of the medical research company's stock after purchasing an additional 113,603 shares during the
Dimensional Fund Advisors LP raised its position in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 12.3% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,188,864 shares of the medical research company's stock after buying an additional 239,313 shares
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with CSL Limited Sponsored ADR (CSLLY) and Exact Sciences (EXAS). But which of these two stocks presents investors with the better value opportunity right now?
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it has earned the 2026 Gallup Exceptional Workplace Award (GEWA), marking the third consecutive year the company has received this prestigious recognition. The award honors organizations with some of the most engaged workplace cultures in the world. Gallup recognized Exact Sciences for fostering a culture where employees feel valued and connected to t.
WILMINGTON, Del.--(BUSINESS WIRE)-- #AIinHealthcare--Amalgam Rx, Inc., a leader in data-driven, AI-powered healthcare engagement and clinical decision support, today announced results from a Privia Health (NASDAQ: PRVA)-led colorectal cancer (CRC) screening program, supported by Amalgam Rx, Inc. and Exact Sciences Corp. (NASDAQ: EXAS). Documented in a published Privia Health case study, the program demonstrates how EHR-integrated workflows and proactive patient outreach supported an increase of CRC screening rat.
DNB Asset Management AS boosted its position in Exact Sciences Corporation (NASDAQ: EXAS) by 15.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 246,639 shares of the medical research company's stock after purchasing an additional 33,071 shares
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corporation (NASDAQ: EXAS) (“Exact Sciences”), a leading provider of cancer screening and diagnostic tests, today announced that its stockholders voted to approve the proposed acquisition of Exact Sciences by Abbott (NYSE: ABT) at the special meeting of stockholders held earlier today. At the special meeting, preliminary results showed that more than 99% of the votes cast, representing approximately 67% of the total outstanding shares of Exact Scie.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EXAS posts Q4 revenue beat as Screening and Precision Oncology grow, margins expand, shares tick up and Abbott merger plans progress.
Aberdeen Group plc raised its holdings in shares of Exact Sciences Corporation (NASDAQ: EXAS) by 52.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 304,609 shares of the medical research company's stock after acquiring an additional 105,138 shares during the quarter.